DeepQure, a company pioneering next-generation solutions for hypertension treatment, has appointed Jason G. Jones as its Global Vice President of Clinical & Regulatory Affairs.
Jones brings more than two decades of expertise in clinical and regulatory leadership, having successfully guided pivotal trials and regulatory approvals at several leading medtech companies.
He most recently served at SoniVie, an Israeli company developing catheter-based intravascular ultrasound renal denervation (RDN) technology. During his tenure, Jones spearheaded the company’s global clinical development strategy and operations, overseeing the completion of enrollment for its Early Feasibility Study (EFS) IDE and advancing its ongoing pivotal IDE.
In March 2025, Boston Scientific acquired SoniVie for US$540 million, underscoring the value of the programs he helped shape.
At DeepQure, Jones will play a critical role in accelerating the company’s global clinical trial activities and supporting the worldwide rollout of its flagship therapy, HyperQure™.
.webp "AngioInsight Appoints Medtech Veteran Shlomi Nachman to Board of Directors")
